EN | RU
EN | RU

Help Support

Back

Study determines efficacy of galcanezumab for management of migraine

migraine_management migraine_management
migraine_management migraine_management

What's new?

Galcanezumab is effective and safe to treat people with migraine.

A study published in Cephalalgia offered real-world evidence of galcanezumab therapy benefits in Asian people suffering from migraine. Soonwook Kwon et al. sought to offer real-world data on  effectiveness of the monoclonal antibody galcanezumab for migraine management. The study prospectively enrolled migraine people who were given galcanezumab therapy. The therapeutic response was evaluated following 3 consecutive monthly injections.

A 50% responder rate was assessed on the basis of ≥50% decline in number of severe/moderate headache days. A total of 87 people (83.9% females, mean age 41.7 ± 12.3 years) were incorporated. In total, 35 subjects (40.2%) had a history of medicine-overuse headache, 65 subjects (74.7%) had chronic migraine, and 32 subjects (36.8%) were previously not responsive or intolerable to 5 classes of preventive medicines.

Following 3 months of therapy the mean alteration in the numbers of monthly headache days, days of acute medication use, moderate/severe headache days, and crystal clear days, are shown in Table 1:

The 50% responder rates were found to be 58.3%, 44.2%, and 40.6% for people having unsuccessful prior usage of 0-1, 2-4, and 5 preventive medicine classes, respectively. A substantial reduction in Headache Impact Test-6 (HIT-6) and Migraine Disability Assessment Test (MIDAS) scores were also witnessed, as shown in Table 2:

The effectiveness and safety of galcanezumab were comparable to that stated in clinical trials. Furthermore, a greater response rate was noted in the difficult-to-treat participant subset when compared to that noted in trials. Hence, the use of anti-calcitonin gene-related peptide (anti-CGRP) agent galcanezumab is beneficial for the management of migraine.

 

Source:

Cephalalgia

Article:

Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients

Authors:

Soonwook Kwon et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: